Breathing hope: fighting the lung disease pulmonary fibrosis
The animation and accompanying article aims to draw attention to and raise awareness about pulmonary fibrosis, a disease often misdiagnosed an overlooked.
From caregiver to co-founder of the European Pulmonary Fibrosis Federation, Liam Galvin shares about his experience, and the impact of ongoing research
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Listen to Steve Jones (a person living wih IPF) and Dr. Marlies Wijsenbeek (a leading pulmonologist) discuss the importance of treatment discussions in IPF
Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.